Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


Aureus Pharma Releases AurPROFILER - a new and powerful pharmacology profiling solution


Paris, France (August 18, 2008) - Aureus Pharma, a leading provider of knowledge management solutions that accelerate life science discovery, announced the release today of the new software solution AurPROFILER®.

AurPROFILER enables researchers to rapidly evaluate target, cell and drug profiles using bio-assays derived from the activity data found in Aureus Pharma’s AurSCOPE Target Knowledge databases. AurPROFILER has been designed to work in conjunction with the just released AurSCOPE® Global Pharmacology Space and all of Aureus’ drug target focused knowledge databases.

Compound profiling is routinely used by pharmaceutical researchers to evaluate the critical issues of drug target selectivity including off-target effects, polypharmacology and cytotoxicity. With easily interpretable graphics, AurPROFILER provides valuable insights to help better manage these issues by rapidly providing in-silico profiles. AurPROFILER results facilitate better discovery team decision making, and reduce risk to that streamline drug discovery projects. AurPROFILER was developed in collaboration with a pharmaceutical industry focus group consisting of several major pharmaceutical companies.

“After intensive development and customer validation, we are delighted to release AurPROFILER.” said Jason Theodosiou, President and CEO of Aureus Pharma. “AurPROFILER is an example where the combination of Aureus’ analysis capabilities and the high quality data within AurSCOPE Knowledge databases combine to bring additional value to researchers.”

Aureus Pharma experts will demonstrate AurPROFILER at the American Chemical Society (ACS) meeting in Philadelphia, PA August 18th -21st.

About Aureus Pharma
Aureus Pharma headquartered in Paris, France is a privately held knowledge management based solutions provider for the life sciences industry. Aureus Pharma accelerates new drug discovery by providing knowledge databases which contain high quality quantitative information for both chemistry and biology.

Researchers gain rapid access to knowledge for important drug target classes as well as ADME/Tox topics. The information contained in the Aureus Pharma system is of primary importance to aid in lead discovery and optimization as well as to build predictive models. Aureus delivers its information in the AurSCOPE format. The AurSCOPE product line includes: AurSCOPE GPCR, AurSCOPE Ion Channel, AurSCOPE Kinase, AurSCOPE Nuclear Receptors, AurSCOPE Proteases and AurSCOPE Global Pharmacology Space. For further information on how Aureus Pharma helps researchers turn data into discovery visit www.aureuspharma.com

Media Contact

Mary E. Donlan, Ph.D.
Director of Marketing
Aureus Pharma
Phone: +33 1 40 18 57 59 / +33 6 76 19 51 77
mary.donlan@aureus-pharma.com


Publisher Contact Information:

Aureus Pharma
+33 1 40 18 57 59
mary.donlan@aureus-pharma.com

Company profile of Aureus Sciences
Past press releases of Aureus Sciences.

Data


25,894
Tech investments
From our Online Data Service
16,759
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Jun 29€1.3MSecurity
Jun 28€2.2MDatabase
Jun 28€12.0MMaterials
Jun 28€5.5MBusiness applications
Jun 27€3.0MBiopharmaceuticals
Jun 27€10.0MEnergy related
Jun 27N/AWireless applications

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.